■淋巴管平滑肌瘤病(LAM)是一种罕见的多系统疾病,其特征是异常平滑肌样细胞的增殖。尽管血清血管内皮生长因子-D(VEGF-D)目前被用作LAM的诊断生物标志物,其在韩国患者中的诊断价值尚不清楚.
■评价血清VEGF-D对韩国患者LAM的诊断价值。
■多中心前瞻性队列研究。
■前瞻性地从五家医疗机构收集血清样本,LAM患者(n=40)和对照组(n=24;健康参与者=3,其他囊性肺病=13,特发性肺纤维化=4,特发性非特异性间质性肺炎=4).采用酶联免疫吸附试验检测血清VEGF-D水平,并使用受试者工作特征(ROC)曲线分析评估诊断价值。
■LAM患者的平均年龄为44.5岁,全部为女性(对照组:47.8岁;女性:70.8%,p<0.001)。LAM患者的血清VEGF-D水平明显高于对照组(中位数:708.9pg/mLvs325.3pg/mL,p<0.001)。在ROC曲线分析中,血清VEGF-D水平对LAM诊断具有良好的预测性能(曲线下面积=0.918),最佳临界值为432.7pg/mL(灵敏度=85.0%,特异性=87.5%)。当800pg/mL用作截止值时,血清VEGF-D对LAM诊断的特异性提高至100.0%。
■我们的结果表明,血清VEGF-D可能是诊断韩国患者LAM的有用生物标志物,类似于以前的报道。
韩国淋巴管平滑肌瘤病诊断的血液检测:血管内皮生长因子-D在本研究中的作用,我们讨论血液检查来诊断一种罕见的肺部疾病,称为淋巴管平滑肌瘤病(LAM)。LAM主要影响女性,尤其是在他们的生育年龄,并可能导致严重的肺部问题,如损伤和囊肿(充气囊)形成。验血在血液中寻找一种特殊的蛋白质,血管内皮生长因子-D(VEGF-D)。如果有人有很多这种蛋白质,这通常意味着他们有林。我们发现当VEGF-D水平很高时,该测试可以有效地将LAM与其他肺部疾病分开。我们还发现,将此阈值提高到更高的水平,可以更有可能正确区分一组没有这种疾病的人与LAM患者。我们的研究很重要,因为它是第一个显示血液VEGF-D检测在韩国LAM患者中的有用性的研究,因为它为医生诊断韩国人的LAM提供了一种更简单、更不方便的方法。我们的发现是改善韩国LAM患者管理的重要一步。
UNASSIGNED: Lymphangioleiomyomatosis (LAM) is a rare multisystemic disorder characterized by the proliferation of abnormal smooth muscle-like cells. Although serum vascular endothelial growth factor-D (VEGF-D) is currently used as a diagnostic biomarker for LAM, its diagnostic value in Korean patients is unclear.
UNASSIGNED: To evaluate the diagnostic value of serum VEGF-D for LAM in Korean patients.
UNASSIGNED: A multicenter prospective cohort study.
UNASSIGNED: Serum samples were prospectively collected from five medical institutions, from patients with LAM (n = 40) and controls (n = 24; healthy participants = 3, other cystic lung diseases = 13, idiopathic pulmonary fibrosis = 4, idiopathic nonspecific interstitial pneumonia = 4). Serum VEGF-D levels were measured using the enzyme-linked immunosorbent assay, and the diagnostic value was evaluated using receiver operating characteristic (ROC) curve analysis.
UNASSIGNED: The mean age of patients with LAM was 44.5 years, and all were female (controls: 47.8 years; female: 70.8%, p < 0.001). The serum VEGF-D levels were significantly higher in patients with LAM than those in the control group (median: 708.9 pg/mL vs 325.3 pg/mL, p < 0.001). In the ROC curve analysis, serum VEGF-D levels showed good predicting performance for LAM
diagnosis (area under the curve = 0.918) with an optimal cut-off value of 432.7 pg/mL (sensitivity = 85.0%, specificity = 87.5%). When 800 pg/mL was used as the cut-off value, the specificity of serum VEGF-D for LAM
diagnosis increased to 100.0%.
UNASSIGNED: Our results suggest that serum VEGF-D may be a useful biomarker for diagnosing LAM in Korean patients, similar to previous reports.
Blood test for
diagnosis of lymphangioleiomyomatosis in Korea: role of vascular endothelial growth factor-DIn this study, we discuss a blood test to diagnose a rare lung disease, called lymphangioleiomyomatosis (LAM). LAM primarily affects women, especially during their childbearing years, and can cause serious lung problems such as damage and cyst (air-filled sac) formation. The blood test looks for a special protein in the blood, called vascular endothelial growth factor-D (VEGF-D). If someone has a lot of this protein, it usually means that they have LAM. We have found that when VEGF-D levels are high, the test can effectively separate LAM from other lung diseases. We also found that raising this threshold to higher levels made it much more likely to correctly distinguish a group of people who do not have the disease from patients with LAM. Our study is important because it’s the first to show the usefulness of blood VEGF-D testing in Korean LAM patients, and because it suggests an easier and less inconvenient way for physicians to diagnose LAM in Koreans. Our findings are an important step in improving the management of Korean patients with LAM.